AI-Driven MRI Radiomics Predicts Liver Cancer Therapy Response

June 1, 2025

AI-powered MRI radiomics significantly improves prediction of treatment response in advanced liver cancer patients.

Key Details

  • Multicenter study presented at ASCO 2025 focused on advanced hepatocellular carcinoma (HCC).
  • AI-based radiomics model analyzed MRI data to predict response to atezolizumab and bevacizumab therapy.
  • Study included 240 patients; training cohort of 161, validation cohort of 79.
  • Radiomics model achieved AUC of 0.913 (training) and 0.825 (validation); combined with a key MRI feature, AUC increased to 0.951 and 0.835, respectively.
  • Significant correlation found between radiomic and conventional MRI features for intrahepatic lesions.

Why It Matters

This work demonstrates the power of AI-driven radiomics to personalize cancer treatment planning, improve patient selection for liver cancer therapies, and highlights growing integration of advanced imaging analytics in clinical oncology workflows.

Read more

Ready to Sharpen Your Edge?

Join hundreds of your peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.